Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 199,803,280
  • Shares Outstanding, K 5,967,840
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 1.01
  • Price/Sales 3.79
  • Price/Cash Flow 9.92
  • Price/Book 3.40

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.99 +1.00%
on 07/13/17
34.21 -2.60%
on 06/26/17
-0.85 (-2.49%)
since 06/23/17
3-Month
31.67 +5.21%
on 06/08/17
34.48 -3.36%
on 06/22/17
-0.42 (-1.24%)
since 04/24/17
52-Week
29.83 +11.70%
on 11/03/16
37.39 -10.89%
on 08/01/16
-3.42 (-9.31%)
since 07/22/16

Most Recent Stories

More News
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

ZTS : 63.29 (+0.21%)
CLVS : 87.04 (+0.46%)
PFE : 33.32 (-0.48%)
MKGAF : 114.5000 (-1.29%)
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

XLV : 80.96 (-0.04%)
VHT : 150.75 (+0.13%)
MRK : 62.57 (-0.10%)
IYH : 169.87 (+0.04%)
FHLC : 39.13 (+0.13%)
ABBV : 73.91 (-0.96%)
GILD : 74.39 (+0.85%)
AMGN : 181.06 (+0.47%)
PFE : 33.32 (-0.48%)
BMY : 55.60 (-0.09%)
Pfizer Inc (PFE) Approaches New Downside Target of $33.29

Shares of Pfizer Inc (NYSE:PFE) opened today below their pivot of $33.48 and have already reached the first level of support at $33.39. Should the shares continue to fall, the support pivots of $33.29...

PFE : 33.32 (-0.48%)
What to Expect from Anthem (ANTM) this Earnings Season?

Anthem's (ANTM) second-quarter earnings are likely to be supported by robust medical enrollment. However, rising level of SG&A expenses might put pressure on the bottom line.

HUM : 235.50 (-0.18%)
ANTM : 191.00 (+0.18%)
ALGN : 161.19 (+1.46%)
PFE : 33.32 (-0.48%)
Centene (CNC) to Report Q2 Earnings: What's in the Cards?

Centene's (CNC) second-quarter earnings are likely to be driven by Health Net buyout. However, surging level of SG&A expenses might put pressure on the bottom line.

HUM : 235.50 (-0.18%)
CNC : 84.20 (-0.63%)
ALGN : 161.19 (+1.46%)
PFE : 33.32 (-0.48%)
Universal Health (UHS) Q2 Earnings: What's in the Cards?

Universal Health's (UHS) second-quarter earnings are likely to be boosted by solid revenue growth. However, increasing cost of debt might hurt the bottom line.

HUM : 235.50 (-0.18%)
UHS : 124.33 (-0.07%)
ALGN : 161.19 (+1.46%)
PFE : 33.32 (-0.48%)
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin(R)(1) (bevacizumab)

Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin(R) (bevacizumab), met its primary...

PFE : 33.32 (-0.48%)
Featured Company News - Pfizer and Merck Announce EMA'S CHMP Positive Opinion for Avelumab

MAIN, GERMANY / ACCESSWIRE / July 24, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Pfizer Inc. (NYSE: PFE), following which we have published a...

MRK : 62.57 (-0.10%)
PFE : 33.32 (-0.48%)
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

XLV : 80.96 (-0.04%)
VHT : 150.75 (+0.13%)
MRK : 62.57 (-0.10%)
IYH : 169.87 (+0.04%)
FHLC : 39.13 (+0.13%)
ABBV : 73.91 (-0.96%)
GILD : 74.39 (+0.85%)
AMGN : 181.06 (+0.47%)
PFE : 33.32 (-0.48%)
BMY : 55.60 (-0.09%)
Merck's Biosimilar Insulin Gets Tentative FDA Approval

Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

MRK : 62.57 (-0.10%)
LLY : 84.74 (+0.09%)
PFE : 33.32 (-0.48%)
SNY : 47.71 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 33.58
1st Resistance Point 33.45
Last Price 33.32
1st Support Level 33.18
2nd Support Level 33.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.